

# Jan H Beumer

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/6692090/jan-h-beumer-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

155  
papers

3,542  
citations

35  
h-index

51  
g-index

164  
ext. papers

4,157  
ext. citations

5.1  
avg. IF

5.11  
L-index

#	Paper	IF	Citations
155	Gene Expression and Cellular Copper Levels between Low and Highly Metastatic Osteosarcoma Provide a Case for Novel Repurposing with Disulfiram and Copper.. <i>Sarcoma</i> , <b>2022</b> , 2022, 7157507	3.1	0
154	Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice.. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2022</b> , 89, 231	3.5	1
153	A phase 1 and pharmacodynamic study of chronically-dosed, single-agent veliparib (ABT-888) in patients with BRCA1- or BRCA2-mutated cancer or platinum-refractory ovarian or triple-negative breast cancer.. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2022</b> , 89, 721	3.5	0
152	Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice.. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2022</b> , 1	3.5	0
151	A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 1	3.5	1
150	Phase 1 study of safety, pharmacokinetics, and pharmacodynamics of tivantinib in combination with bevacizumab in adult patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2021</b> , 88, 643-654	3.5	0
149	Neratinib-Plus-Cetuximab in Quadruple-WT () Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study. <i>Clinical Cancer Research</i> , <b>2021</b> , 27, 1612-1622	12.9	3
148	Improved chemosensitivity following mucolytic therapy in patient-derived models of mucinous appendix cancer. <i>Translational Research</i> , <b>2021</b> , 229, 100-114	11	2
147	Secondary Cytoreduction and Carboplatin Hyperthermic Intraperitoneal Chemotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: An MSK Team Ovary Phase II Study. <i>Journal of Clinical Oncology</i> , <b>2021</b> , 39, 2594-2604	2.2	9
146	Effect of removing race from glomerular filtration rate-estimating equations on anticancer drug dosing and eligibility: a retrospective analysis of National Cancer Institute phase 1 clinical trial participants. <i>Lancet Oncology, The</i> , <b>2021</b> , 22, 1333-1340	21.7	5
145	Development and validation of an LC-MS/MS generic assay platform for small molecule drug bioanalysis. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2021</b> , 203, 114185	3.5	0
144	Precision Dosing of Targeted Therapies Is Ready for Prime Time. <i>Clinical Cancer Research</i> , <b>2021</b> ,	12.9	1
143	Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL. <i>Blood Advances</i> , <b>2021</b> , 5, 4691-4700	7.8	1
142	Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice. <i>Current Reviews in Clinical and Experimental Pharmacology</i> , <b>2021</b> , 16, 263-272		0
141	Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 741-751	3.5	12
140	In vitro evaluation of the metabolic enzymes and drug interaction potential of triapine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 633-640	3.5	2
139	Quantitation of iohexol, a glomerular filtration marker, in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2020</b> , 189, 113464	3.5	4

138	Triple drugs co-delivered by a small gemcitabine-based carrier for pancreatic cancer immunochemotherapy. <i>Acta Biomaterialia</i> , <b>2020</b> , 106, 289-300	10.8	17
137	Evaluation of the pharmacokinetic drug-drug interaction potential of iohexol, a renal filtration marker. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 86, 535-545	3.5	1
136	Phase 1 study of the Aurora kinase A inhibitor alisertib (MLN8237) combined with the histone deacetylase inhibitor vorinostat in lymphoid malignancies. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 309-317	1.9	8
135	Intravenous 5-fluoro-2-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2020</b> , 85, 979-993	3.5	9
134	Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10. <i>Journal of Clinical Oncology</i> , <b>2019</b> , 37, 2601-2609	2.2	27
133	Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1201-1208	3.5	5
132	Quantitation of paclitaxel, and its 6-alpha-OH and 3-para-OH metabolites in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2019</b> , 172, 26-32	3.5	6
131	Estimation of Kidney Function in Oncology: Implications for Anticancer Drug Selection and Dosing. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2019</b> , 14, 587-595	6.9	29
130	Combination Therapy with Disulfiram, Copper, and Doxorubicin for Osteosarcoma: Support for a Novel Drug Repurposing Strategy. <i>Sarcoma</i> , <b>2019</b> , 2019, 1320201	3.1	7
129	A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction. <i>British Journal of Clinical Pharmacology</i> , <b>2019</b> , 85, 2499-2511	3.8	7
128	Phase 1 study of veliparib (ABT-888), a poly (ADP-ribose) polymerase inhibitor, with carboplatin and paclitaxel in advanced solid malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 84, 1289-1301	3.5	18
127	Population pharmacokinetics and exposure-response assessment of veliparib co-administered with temozolomide in patients with myeloid leukemias. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 319-328	3.5	3
126	Oligoadenylate-Synthetase-Family Protein OASL Inhibits Activity of the DNA Sensor cGAS during DNA Virus Infection to Limit Interferon Production. <i>Immunity</i> , <b>2019</b> , 50, 51-63.e5	32.3	44
125	A window-of-opportunity clinical trial of dasatinib in women with newly diagnosed endometrial cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2019</b> , 83, 473-482	3.5	3
124	Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5-Fluorouracil Therapy. <i>Clinical Pharmacology and Therapeutics</i> , <b>2019</b> , 105, 598-613	6.1	46
123	A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , <b>2018</b> , 59, 2595-2601	1.9	7
122	Development and Validation of a Bioanalytical Method to Quantitate Enzalutamide and its Active Metabolite N-Desmethylenzalutamide in Human Plasma: Application to Clinical Management of Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Therapeutic Drug Monitoring</i> , <b>2018</b> , 40, 222-229	3.2	8
121	Targeting p53-dependent stem cell loss for intestinal chemoprotection. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	30

120	Evaluation of Biodistribution of Sulforaphane after Administration of Oral Broccoli Sprout Extract in Melanoma Patients with Multiple Atypical Nevi. <i>Cancer Prevention Research</i> , <b>2018</b> , 11, 429-438	3.2	38
119	Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease. <i>Biology of Blood and Marrow Transplantation</i> , <b>2018</b> , 24, 373-380	4.7	9
118	NCI Comparative Oncology Program Testing of Non-Camptothecin Indenoisoquinoline Topoisomerase I Inhibitors in Naturally Occurring Canine Lymphoma. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 5830-5840	12.9	26
117	Liquid chromatography-tandem mass spectrometric assay for the quantitation of the novel radiation protective agent and radiation mitigator JP4-039 in murine plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2018</b> , 150, 169-175	3.5	6
116	Phase IB trial of ixabepilone and vorinostat in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , <b>2018</b> , 167, 469-478	4.4	16
115	ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation. <i>Journal of Clinical Investigation</i> , <b>2018</b> , 128, 3926-3940	15.9	88
114	Evaluation of Different Formulations and Routes for the Delivery of the Ionizing Radiation Mitigator GS-Nitroxide (JP4-039). <i>In Vivo</i> , <b>2018</b> , 32, 1009-1023	2.3	6
113	Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation. <i>Scientific Reports</i> , <b>2017</b> , 7, 41892	4.9	11
112	Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2017</b> , 144, 459-467	4.9	45
111	RAD-ADAPT: Software for modelling clonogenic assay data in radiation biology. <i>DNA Repair</i> , <b>2017</b> , 52, 24-30	4.3	2
110	Simultaneous quantitation of abiraterone, enzalutamide, N-desmethyl enzalutamide, and bicalutamide in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 138, 197-205	3.5	22
109	Parent-Metabolite Pharmacokinetic Modeling and Pharmacodynamics of Veliparib (ABT-888), a PARP Inhibitor, in Patients With BRCA 1/2-Mutated Cancer or PARP-Sensitive Tumor Types. <i>Journal of Clinical Pharmacology</i> , <b>2017</b> , 57, 977-987	2.9	13
108	Reduced-Concentration Clavulanate for Young Children with Acute Otitis Media. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	7
107	Analytical challenges in quantifying abiraterone with LC-MS/MS in human plasma. <i>Biomedical Chromatography</i> , <b>2017</b> , 31, e3986	1.7	15
106	LC-MS/MS assay for the simultaneous quantitation of the ATM inhibitor AZ31 and the ATR inhibitor AZD6738 in mouse plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 138, 158-165	3.5	2
105	A phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 236-242	4.9	14
104	Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline - or -Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4066-4076	12.9	69
103	A stratified randomized double-blind phase II trial of celecoxib for treating patients with cervical intraepithelial neoplasia: The potential predictive value of VEGF serum levels: An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 291-297	4.9	11

102	The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4119-4126	12.9	13
101	Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin A. <i>Journal of the National Cancer Institute</i> , <b>2017</b> , 109,	9.7	21
100	LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 146, 154-160	3.5	3
99	LC-MS/MS assay for the quantitation of the ATR kinase inhibitor VX-970 in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 146, 244-250	3.5	1
98	Rapid Homogeneous Immunoassay to Quantify Gemcitabine in Plasma for Therapeutic Drug Monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2017</b> , 39, 235-242	3.2	2
97	Phase I study of veliparib in combination with gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 80, 631-643	3.5	9
96	Estimation of body surface area in the musk shrew ( <i>Suncus murinus</i> ): a small animal for testing chemotherapy-induced emesis. <i>Laboratory Animals</i> , <b>2017</b> , 51, 534-537	2.6	4
95	A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 697-706	12.9	40
94	Tyrosine Kinase and Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Practical Clinical Implications of Pharmacologic Features. <i>Clinical Genitourinary Cancer</i> , <b>2017</b> , 15, 7-22	3.3	1
93	LC-MS/MS assay for the quantitation of the tyrosine kinase inhibitor neratinib in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2017</b> , 134, 130-136	3.5	15
92	Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2017</b> , 79, 201-207	3.5	31
91	Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program-Sponsored Single-Agent Phase I Studies. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 110-6	2.2	20
90	LC-MS/MS assay for the quantitation of FdCyd and its metabolites FdUrd and FU in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2016</b> , 129, 359-366	3.5	6
89	Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 1225-1235	3.5	7
88	Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer. <i>Clinical Cancer Research</i> , <b>2016</b> , 22, 2855-64	12.9	57
87	Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 515-26	3.5	16
86	A pharmacokinetic analysis of cisplatin and 5-fluorouracil in a patient with esophageal cancer on peritoneal dialysis. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 77, 333-8	3.5	9
85	Reply to V. Launay-Vacher, T. Shimokata et al, and C. Porta et al. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 2430-1	2.2	

84	Therapeutic drug monitoring of 5-fluorouracil. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 447-64	3.5	110
83	Clinical and pharmacologic evaluation of two dosing schedules of indotecan (LMP400), a novel indenoisoquinoline, in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 73-81	3.5	24
82	Phase I and pharmacokinetic evaluation of the anti-telomerase agent KML-001 with cisplatin in advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2016</b> , 78, 959-967	3.5	5
81	Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 143-52	3.5	11
80	Characterization of the metabolism of benzaldehyde dimethane sulfonate (NSC 281612, DMS612). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 537-46	3.5	3
79	In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of pyrazole-based small molecule inhibitors of Mdm2/4-p53 interaction. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 287-99	3.5	1
78	Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 1015-23	3.5	2
77	A phase I study of DMS612, a novel bifunctional alkylating agent. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 721-9	2.9	7
76	Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627). <i>Neuro-Oncology</i> , <b>2015</b> , 17, 992-8	1	83
75	Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 813-9	3.5	11
74	Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma. <i>BMC Cancer</i> , <b>2015</b> , 15, 649	4.8	8
73	Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation. <i>British Journal of Clinical Pharmacology</i> , <b>2015</b> , 80, 1097-108	3.8	6
72	An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma. <i>Therapeutic Drug Monitoring</i> , <b>2015</b> , 37, 486-92	3.2	6
71	Combined PDGFR and HDAC Inhibition Overcomes PTEN Disruption in Chordoma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0134426	3.7	23
70	Oral and intravenous pharmacokinetics of 5-fluoro-2-deoxythymine and THU in cynomolgus monkeys and humans. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 76, 803-11	3.5	14
69	A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2-deoxythymine, administered with tetrahydrouridine. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2015</b> , 75, 537-46	3.5	43
68	A quasi-quantitative dual multiplexed immunoblot method to simultaneously analyze ATM and H2AX Phosphorylation in human peripheral blood mononuclear cells. <i>Oncoscience</i> , <b>2015</b> , 2, 542-54	0.8	10
67	Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial. <i>Lancet Oncology</i> , <b>2014</b> , 15, 87-95	21.7	100

66	Calcium carbonate does not affect imatinib pharmacokinetics in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 73, 207-11	3.5	3
65	Quantitative method for the determination of iso-fludelone (KOS-1803) in human plasma by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2014</b> , 100, 199-204	3.5	1
64	Clove extract inhibits tumor growth and promotes cell cycle arrest and apoptosis. <i>Oncology Research</i> , <b>2014</b> , 21, 247-59	4.8	53
63	Effect of age on the pharmacokinetics of busulfan in patients undergoing hematopoietic cell transplantation; an alliance study (CALGB 10503, 19808, and 100103). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2014</b> , 74, 927-38	3.5	16
62	Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer. <i>Cancer Medicine</i> , <b>2014</b> , 3, 1579-94	4.8	58
61	Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer. <i>Journal of Clinical Pharmacology</i> , <b>2014</b> , 54, 1272-9	2.9	5
60	VDR activity is differentially affected by Hic-5 in prostate cancer and stromal cells. <i>Molecular Cancer Research</i> , <b>2014</b> , 12, 1166-80	6.6	14
59	ABCB1, ABCG2, and PTEN determine the response of glioblastoma to temozolomide and ABT-888 therapy. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 2703-13	12.9	83
58	The potential roles of hepatocyte growth factor (HGF)-MET pathway inhibitors in cancer treatment. <i>OncoTargets and Therapy</i> , <b>2014</b> , 7, 969-83	4.4	42
57	Formation of active products of benzaldehyde dimethane sulfonate (NSC 281612, DMS612) in human blood and plasma and their activity against renal cell carcinoma lines. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 73-83	3.5	4
56	Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 1143-7	3.5	4
55	Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 72, 1195-204	3.5	6
54	LC-MS/MS assay for the quantitation of the HDAC inhibitor belinostat and five major metabolites in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2013</b> , 81-82, 89-98	3.5	12
53	In vitro cytotoxicity, pharmacokinetics, tissue distribution, and metabolism of small-molecule protein kinase D inhibitors, kb-NB142-70 and kb-NB165-09, in mice bearing human cancer xenografts. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2013</b> , 71, 331-44	3.5	15
52	Without therapeutic drug monitoring, there is no personalized cancer care. <i>Clinical Pharmacology and Therapeutics</i> , <b>2013</b> , 93, 228-30	6.1	36
51	A phase II trial of dasatinib in patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy. <i>Anti-Cancer Drugs</i> , <b>2013</b> , 24, 743-53	2.4	35
50	Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 1843-51	4	20
49	Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia. <i>Clinical Cancer Research</i> , <b>2013</b> , 19, 1838-51	12.9	40

48	Comparing histone deacetylase inhibitor responses in genetically engineered mouse lung cancer models and a window of opportunity trial in patients with lung cancer. <i>Molecular Cancer Therapeutics</i> , <b>2013</b> , 12, 1545-55	6.1	16
47	ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage. <i>Nucleic Acids Research</i> , <b>2013</b> , 41, 10334-44	20.1	52
46	Radiation therapy induces the DNA damage response in peripheral blood. <i>Oncotarget</i> , <b>2013</b> , 4, 1143-8	3.3	13
45	A Novel Sequestosome-1/p62 ZZ Domain Inhibitor Induces New Bone Formation In The Presence Of Myeloma In Vivo. <i>Blood</i> , <b>2013</b> , 122, 684-684	2.2	1
44	CYP24 inhibition preserves 1,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. <i>Molecular and Cellular Endocrinology</i> , <b>2012</b> , 355, 153-61	4.4	32
43	Halofuginone infused keratin hydrogel attenuates adhesions in a rodent cecal abrasion model. <i>Journal of Surgical Research</i> , <b>2012</b> , 178, 545-52	2.5	25
42	A local effect of CYP24 inhibition on lung tumor xenograft exposure to 1,25-dihydroxyvitamin D(3) is revealed using a novel LC-MS/MS assay. <i>Steroids</i> , <b>2012</b> , 77, 477-83	2.8	11
41	A Phase I clinical trial of the combination of imatinib and paclitaxel in patients with advanced or metastatic solid tumors refractory to standard therapy. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 70, 843-53	3.5	14
40	Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2012</b> , 69, 1657-67	3.5	18
39	Biomarkers of phenethyl isothiocyanate-mediated mammary cancer chemoprevention in a clinically relevant mouse model. <i>Journal of the National Cancer Institute</i> , <b>2012</b> , 104, 1228-39	9.7	24
38	Body-surface area-based chemotherapy dosing: appropriate in the 21st century?. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 3896-7	2.2	31
37	A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. <i>Clinical Cancer Research</i> , <b>2012</b> , 18, 1726-34	12.9	160
36	Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer. <i>Journal of Thoracic Oncology</i> , <b>2012</b> , 7, 856-65	8.9	33
35	Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2011</b> , 67, 421-30	3.5	9
34	Chemopreventative potential of the cruciferous vegetable constituent phenethyl isothiocyanate in a mouse model of prostate cancer. <i>Journal of the National Cancer Institute</i> , <b>2011</b> , 103, 571-84	9.7	84
33	A Phase 1 Open Label, Dose Escalation Study of Nilotinib in Steroid Dependent/Refractory Chronic Graft-Versus-Host Disease. <i>Blood</i> , <b>2011</b> , 118, 1986-1986	2.2	
32	Phase I study of vorinostat in patients with advanced solid tumors and hepatic dysfunction: a National Cancer Institute Organ Dysfunction Working Group study. <i>Journal of Clinical Oncology</i> , <b>2010</b> , 28, 4507-12	2.2	77
31	Role of histone deacetylases and their inhibitors in cancer biology and treatment. <i>Current Clinical Pharmacology</i> , <b>2010</b> , 5, 196-208	2.5	53



30 Mass Balance Studies **2010**, 1

29	In vitro cytotoxicity and in vivo efficacy, pharmacokinetics, and metabolism of 10074-G5, a novel small-molecule inhibitor of c-Myc/Max dimerization. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2010</b> , 335, 715-27	4.7	77
28	Liquid chromatography-tandem mass spectrometric assay for the quantitation in human plasma of the novel indenoisoquinoline topoisomerase I inhibitors, NSC 743400 and NSC 725776. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , <b>2010</b> , 52, 714-20	3.5	12
27	In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. <i>Journal of Extra-Corporeal Technology</i> , <b>2010</b> , 42, 75-9	0.4	8
26	Sulforaphane inhibits prostate carcinogenesis and pulmonary metastasis in TRAMP mice in association with increased cytotoxicity of natural killer cells. <i>Cancer Research</i> , <b>2009</b> , 69, 2117-25	10.1	155
25	Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743). <i>Current Clinical Pharmacology</i> , <b>2009</b> , 4, 38-42	2.5	10
24	Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS). <i>Drug Metabolism and Pharmacokinetics</i> , <b>2009</b> , 24, 511-22	2.2	20
23	Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. <i>Pharmacotherapy</i> , <b>2009</b> , 29, 1152-6	5.8	29
22	Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. <i>Cancer</i> , <b>2009</b> , 115, 2188-98	6.4	64
21	Disposition of temozolomide in a patient with glioblastoma multiforme after gastric bypass surgery. <i>Journal of Neuro-Oncology</i> , <b>2009</b> , 93, 279-83	4.8	15
20	Effect of antacid on imatinib absorption. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2009</b> , 63, 525-8	3.5	38
19	Effect of a proton pump inhibitor on the pharmacokinetics of imatinib. <i>British Journal of Clinical Pharmacology</i> , <b>2009</b> , 68, 370-4	3.8	48
18	A high-performance liquid chromatography-mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2009</b> , 877, 1894-900	3.2	25
17	Multicenter Evaluation of a Novel Nanoparticle Immunoassay for 5-Fluorouracil on the Olympus AU400 Analyzer. <i>Therapeutic Drug Monitoring</i> , <b>2009</b> , 31, 688-694	3.2	27
16	Modulation of gemcitabine (2,2-difluoro-2-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 3529-35	12.9	44
15	Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 363-8	3.5	63
14	Plasma pharmacokinetics and oral bioavailability of 3,4,5,6-tetrahydrouridine, a cytidine deaminase inhibitor, in mice. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2008</b> , 62, 457-64	3.5	16
13	Quantitation of 5-fluorouracil (5-FU) in human plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , <b>2008</b> , 22, 224-30	2.2	48

12	Liquid chromatography-mass spectrometric assay for quantitation of the short-chain fatty acid, 2,2-dimethylbutyrate (NSC 741804), in rat plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2008</b> , 862, 168-74	3.2	6
11	Liquid chromatography-mass spectrometric assay for the quantitation in human plasma of ABT-888, an orally available, small molecule inhibitor of poly(ADP-ribose) polymerase. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2008</b> , 872, 141-7	3.2	24
10	Highlights from: 5-Fluorouracil Drug Management Pharmacokinetics and Pharmacogenomics Workshop; Orlando, Florida; January 2007. <i>Clinical Colorectal Cancer</i> , <b>2007</b> , 6, 407-22	3.8	16
9	Quantitative determination of the cytidine deaminase inhibitor tetrahydrouridine (THU) in mouse plasma by liquid chromatography/electrospray ionization tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , <b>2007</b> , 21, 1991-7	2.2	10
8	Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer. <i>Cancer Chemotherapy and Pharmacology</i> , <b>2007</b> , 59, 825-37	3.5	24
7	Disposition of imatinib and its metabolite CGP74588 in a patient with chronic myelogenous leukemia and short-bowel syndrome. <i>Pharmacotherapy</i> , <b>2006</b> , 26, 903-7	5.8	22
6	A mass balance and disposition study of the DNA methyltransferase inhibitor zebularine (NSC 309132) and three of its metabolites in mice. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 5826-33	12.9	8
5	Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2-deoxycytidine in mice. <i>Clinical Cancer Research</i> , <b>2006</b> , 12, 7483-91	12.9	48
4	Mass balance studies, with a focus on anticancer drugs. <i>Clinical Pharmacokinetics</i> , <b>2006</b> , 45, 33-58	6.2	67
3	Quantitative determination of zebularine (NSC 309132), a DNA methyltransferase inhibitor, and three metabolites in murine plasma by high-performance liquid chromatography coupled with on-line radioactivity detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2006</b> , 831, 117-55	3.2	12
2	A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamic acid, SAHA), and its metabolites in human serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , <b>2006</b> , 840, 108-15	3.2	49
1	ATR kinase inhibition induces thymineless death in proliferating CD8+ T cells		1